- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07708896
Evolution of Chronic Inflammatory Skin Diseases (EPICA)
monocentric retrospective-prospective observational study evaluating the clinical evolution of common chronic inflammatory skin diseases, including atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study will collect demographic, clinical, therapeutic, and validated clinimetric data from patients aged ≥12 years. Its primary aim is to describe changes in disease severity over time. Secondary objectives include identifying demographic, clinical, and treatment-related predictors of moderate-to-severe disease and unfavorable outcomes. Data will cover a 7-year retrospective period and a 10-year prospective follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ketty Peris
- Phone Number: +390630155701
- Email: ketty.peris@policlinicogemelli.it
Study Locations
-
-
-
Rome, Italy, 00168
- Recruiting
- Fondazione Policlinico Agostino Gemelli IRCCS
-
Contact:
- Ketty Peris, Prof
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
patients affected with inflammatory skin conditions including atopic dermatitis, prurigo nodularis, Hidradenitis suppurativa, psoriasis
Description
Inclusion Criteria:
- Age ≥12 years.
- Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
- Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.
Exclusion Criteria:
- Age <12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
- Refusal or inability to understand and sign the informed consent form.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: OTHER
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change Over Time in Eczema Area and Severity Index (EASI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Eczema Area and Severity Index (EASI) in participants with atopic dermatitis. EASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in SCORing Atopic Dermatitis (SCORAD)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in SCORing Atopic Dermatitis (SCORAD) in participants with atopic dermatitis. SCORAD ranges from 0 to 103, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Patient-Oriented Eczema Measure (POEM)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Patient-Oriented Eczema Measure (POEM) in participants with atopic dermatitis. POEM ranges from 0 to 28, with higher scores indicating greater patient-reported disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Psoriasis Area and Severity Index (PASI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Psoriasis Area and Severity Index (PASI) in participants with psoriasis. PASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hand Eczema Severity Index (HECSI)
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Hand Eczema Severity Index (HECSI) in participants with chronic hand eczema. HECSI ranges from 0 to 360, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Investigator's Global Assessment for Prurigo Nodularis
Time Frame: Baseline and every 16 ± 4 weeks, up to 120 months
|
Change in Investigator Global Assessment (IGA) in patients with prurigo nodularis |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Itch Numerical Rating Scale (NRS)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in itch intensity assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, where 0 indicates no itch and 10 indicates the worst imaginable itch. Higher scores indicate worse itch. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Sleep Numerical Rating Scale (NRS)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in sleep disturbance assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, with higher scores indicating greater sleep disturbance. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Dermatology Life Quality Index (DLQI)
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Dermatology Life Quality Index (DLQI). Scores range from 0 to 30, with higher scores indicating greater impairment in dermatology-related quality of life. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hurley Stage
Time Frame: baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in hidradenitis suppurativa severity according to Hurley staging. Hurley stage ranges from Stage I to Stage III, with higher stages indicating more severe disease. |
baseline and every 16 ± 4 weeks, up to 120 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ketty Peris, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 27085
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.